ATHEROSCLEROSIS / RESEARCH PAPER
The effect of PCSK9 immunization on the hepatic level of microRNAs associated with PCSK9/LDLR pathway.
More details
Hide details
1 |
Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran |
2 |
Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran |
3 |
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland, Poland |
4 |
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran |
CORRESPONDING AUTHOR
Maciej Banach
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland, Rzgowska 281/289, 93-338, Lodz, Poland
Submission date: 2022-06-19
Final revision date: 2022-06-27
Acceptance date: 2022-07-09
Publication date: 2022-07-09
Arch Med Sci 2022;18(6)
KEYWORDS
TOPICS
ABSTRACT
Introduction:
We aimed aimed to assess the effect of the immunotherapy with the PCSK9 peptide vaccine on the hepatic expression levels of microRNAs associated with LDLR pathway including miRNA-27a, miRNA-30c, and miRNA-191 in normal vaccinated mice.
Material and methods:
PCSK9 immunogenic peptide and 0.4% alum adjuvant were mixed at a 1:1 ratio and used as a vaccine formulation. Male albino mice were randomly assigned into vaccine or control groups. Mice in the vaccine group were injected four times at two-week intervals with a PCSK9 peptide vaccine, and mice in the control group were injected with phosphate-buffered saline. Animal livers were sampled two weeks after the last injection to assess miRNAs expression levels. The hepatic expression level of miRNA-27a, miRNA-30c, and miRNA-191 were evaluated by SYBR Green Real-Time PCR, quantified by comparative (2-ΔΔCT) method (Fold change) and normalized to U6 small nuclear RNA expression as an internal control.
Results:
The hepatic expression level of miRNA-27a showed significant reduction in mice following immunotherapy with the PCSK9 peptide vaccine when compared to the control group (FC:0.731±0.1, P=0.027). Also, there was a borderline significant reduction in the hepatic expression level of miRNA-30c in the vaccinated group compared to the control (FC: 0.569±0.1, P=0.078). However, no significant differences were found in the hepatic expression level of miRNA-191 between two studied groups (FC: 0.852±0.1, P=0.343).
Conclusions:
According to the findings, the PCSK9 peptide vaccine could effectively reduce the hepatic expression level of miRNA-27a and may be helpful in the management of LDL-C level and atherosclerosis, which may be mediated through LDLR pathway.